Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differential isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 mutation-related landscape in intrahepatic cholangiocarcinoma.

The oncologist - 5 Aug 2024

Xu Shuaishuai, Cao Linping, Chen Ruyin, Ye Chanqi, Li Qiong, Jiang Qi, Yan Feifei, Wan Mingyu, Zhang Xiaochen, Ruan Jian

Abstract excerpt

BACKGROUND: Patients with intrahepatic cholangiocarcinoma (ICC) are prone to recurrence and poor survival. Targeted therapy related to isocitrate dehydrogenase (IDH) is an extremely important treatment. IDH1 and IDH2 mutations are generally thought to have similar effects on the tumor landscape. However, it is doubtful whether these 2 mutations have exactly the same effects on tumor cells and the tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Bile Duct Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholangiocarcinoma

Share to IDH2 gene

Share to PVR gene

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 38842680
DOI: 10.1093/oncolo/oyae132
PMCID: PMC11299938

Genes

IDH2
IDH1
KRAS
PVR
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 mutation-related landscape in intrahepatic cholangiocarcinoma.PMID 38842680Read ↗

Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma.Semantic proximity Read ↗

Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma cells to MDM2 inhibitorsSemantic proximity Read ↗

Molecular Profile of Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

Comprehensive Immunogenomic Profiling of IDH1-/2-Altered Cholangiocarcinoma.Semantic proximity Read ↗

Emergence of Intrahepatic Cholangiocarcinoma: How High-Throughput Technologies Expedite the Solutions for a Rare Cancer TypeSemantic proximity Read ↗

Mutation Rate of IDH1 and the Impact of Pathological Features on Survival in Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism.Semantic proximity Read ↗

Molecular Subtypes and Precision Oncology in Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

IDH Mutation Subgroup Status Associates with Intratumor Heterogeneity and the Tumor Microenvironment in Intrahepatic Cholangiocarcinoma.Semantic proximity Read ↗

Mutational landscape of intrahepatic cholangiocarcinoma.Semantic proximity Read ↗

Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.Semantic proximity Read ↗

Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.